Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 201–300 of 798
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
“GLP-1 is rapidly cleaved by the ubiquitously expressed dipeptidyl peptidase-4 (DPP-4) to GLP-1(9–36), which has a very low affinity for the classical GLP-1 receptor (GLP-1R) [4,5].”
BackgroundGLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 104
Murage, E. N., Gao, G., Bisello, A., & Ahn, J.-M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100602m · Cited by 87
Proglucagon processing in islet and intestinal cell lines
Tucker, J. D., Dhanvantari, S., & Brubaker, P. L. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(95)00167-0 · Cited by 106
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 85
“Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha(1-67) in patients with type 2 diabetes.”
BackgroundKim, S., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2008) · Diabetes · doi:10.2337/db07-1639 · Cited by 96
Shrestha, N., Shahbazi, M., Araújo, F., Mäkilä, E. M., Raula, J., Kauppinen, E. I., Salonen, J., Sarmento, B. F. C. C., Hirvonen, J. J., & Santos, H. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.045 · Cited by 100
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 89
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84
“The very short elimination half-life of native GLP-1, normally released from endocrine cells in the intestine, is due to inactivation by cleavage by DPPIV at the alanine residue at position 2 of the molecule [10,11].”
BackgroundSelf-citationMechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
“GLP-1 is rapidly cleaved between positions 8 and 9 by the widely expressed serine protease DPPIV into GLP-1(9-36)amide (and GLP-1(9-37)) giving a circulation half life of 2–3 min (Mentlein et al., 1993b; Deacon et al., 1995; Kieffer et al., 1995; Hansen et al., 1999).”
BackgroundInvestigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., Minnion, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M., Beale, K. E. L., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2009) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84
Hjøllund, K. R., Deacon, C. F., & Holst, J. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2168-7 · Cited by 84
Self-citationFersing, C., Bouhlel, A., Cantelli, C., Garrigue, P., Lisowski, V., & Guillet, B. A. (2019) · Molecules · doi:10.3390/molecules24162866 · Cited by 88
“4% yield, which could have maybe been optimized by [18F]F− concentration using a ion exchange cartridge and/or adding an organic co-solvent like ethanol or acetonitrile to the reaction medium), [(18)F]AlF-NOTA(5)-MAL-Cys(40)-extendin-4 proved to be stable in human plasma for up to 1 h, which is a critical parameter fo…”
MethodGlucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
Gallwitz, B. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504060-00005 · Cited by 93
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, C. F. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.011 · Cited by 89
“Subsequently, more physiologically relevant (picomolar) levels of GLP-1 were also shown to be degraded by DPP-4 in plasma, and the N-terminally truncated metabolite generated by DPP-4 action was identified as the major circulating form of endogenous GLP-1 in humans, suggesting that DPP-4 was likely to play a physiolog…”
Self-citationGallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“Native GLP-1 is not suitable for treatment, since the peptide is degraded rapidly within minutes by the enzyme dipeptidyl-peptidase-IV (DPP-4) (31, 32).”
BackgroundDPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 95
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
“The degradation of GLP-1 into an insulinotropically inactive form in the presence of 20% serum at 37 C has been reported to have a half-life of approximately 15–20 min (16, 17).”
Yang, G., Lei, Y., Inoue, A., Piao, L., Hu, L., Jiang, H., Sasaki, T., Wu, H., Xu, W., Yu, C., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.014 · Cited by 84
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 79
“This ubiquitously expressed “ectopeptidase” cleaves the N-terminal dipeptide, His7-Ala8, to inactivate GLP-1 [48, 49].”
BackgroundMethodMeier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 88
“Intra-assay and inter-assay coefficients of variation were less than 6 and 15%, respectively, at 40 pmol/l [17].”
BackgroundSelf-citationMeier, J. J., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00289.2007 · Cited by 77
“This procedure has previously been shown to effectively prevent DPP-4 degradation (4).”
BackgroundSelf-citationRibel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Self-citationIncretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
González‐Abuín, N., Martínez-Micaelo, N., Margalef, M., Blay, M., Arola‐Arnal, A., Muguerza, B., Ardèvol, A., & Pinent, M. (2014) · Food & Function · doi:10.1039/c4fo00447g · Cited by 76
Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 83
Self-citationAdvances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 78
“GLP-1 (9–36) is the primary GLP-1 metabolite in vivo, and circulating levels of GLP-1 (9-36) are greater than those of intact bioactive GLP1 [46].”
BackgroundInfluentialBatista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77
Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery
Wootten, D. L., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., FICORILLI, J. V., Showalter, A. D., Willard, F. S., Christopoulos, A., & Sexton, P. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079319 · Cited by 78
“The metabolite is thus the major circulating form of GLP-1; however, it does not stimulate insulin secretion (Deacon et al., 1995; Tomas and Habener, 2010), presumably due to the lack of GLP-1R-mediated increases in cAMP, which is thought to be a major contributor to insulin secretion.”
BackgroundNeurophysiology of hunger and satiety
Smith, P., & Ferguson, A. V. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.13 · Cited by 104
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Self-citationDipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Rosenstock, J., & Zinman, B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280a02f65 · Cited by 81
Ueda, T., Tomita, K., Notsu, Y., Ito, T., Fumoto, M., Takakura, T., Nagatome, H., Takimoto, A., Mihara, S.-I., Togame, H., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900261g · Cited by 76
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00424.x · Cited by 74
Self-citationØrskov, J. J. H. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 71
Self-citationÅhrén, B., & Foley, J. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3899-2 · Cited by 82
GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
“One clinical limitation with the GLP-1 receptor agonist Ex4 is that its metabolized rapidly and extensively (Deacon et al., 1995),”
Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72
Self-citationEnzymes as a special class of therapeutic target: clinical drugs and modes of action
Robertson, J. G. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.08.008 · Cited by 88
Cummings, B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson, C., Sams, A., Knudsen, L. B., Raun, K., & Havel, P. J. (2010) · Diabetes · doi:10.2337/db09-1564 · Cited by 72
“Thus, one method currently being pursued for the therapeutic targeting of GLP-1 is production of GLP-1 analogs that are resistant to degradation by DPP-IV.”
BackgroundInfluentialProglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
The incretins: a link between nutrients and well-being
Burcelin, R. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041340 · Cited by 70
“In the late 1960s it was further demonstrated that an oral glucose load induced a higher insulin secretion than intravenously administered glucose while blood glucose levels were similar between the two modes of delivery, suggesting that glucose clearance was different and involved different…”
The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Deacon, C. F., Plamboeck, A., Rosenkilde, M. M., de Heer, J., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00577.2005 · Cited by 70
Self-citationMetabolism of glucagon by dipeptidyl peptidase IV (CD26)
Pospisilik, J. A., Hinke, S. A., Pederson, R. A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U. F., McIntosh, C. H. S., & Demuth, H. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00170-1 · Cited by 83
Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 74
Luo, G., Liu, H., & Lu, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12777 · Cited by 67
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · Peptides · doi:10.1016/s0196-9781(98)00020-5 · Cited by 75
Self-citationVagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
“Nonetheless, the c-Fos expression pattern after HPV administration of a DPP-IV inhibitor (that raises HPV, but not systemic GLP-1 levels) is to a great extent similar to the expression pattern induced by IP Ex-4 [37].”
InfluentialClinical Impact of Liraglutide as a Treatment of Obesity
Alruwaili, H., Dehestani, B., & le Roux, C. W. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s276085 · Cited by 93
“Once secreted, the half-life of GLP-1 is only a few minutes due to the rapid breakdown by dipeptidyl peptidase-4 (DPP4).(16,17) Liraglutide, a GLP-1 analogue, is 97% homologous”
BackgroundImmunoassays for the incretin hormones GIP and GLP-1
Deacon, C. F., & Holst, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.006 · Cited by 83
Self-citationEvaluation of an [18F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma
Kiesewetter, D. O., Guo, N., Guo, J., Gao, H., Zhu, L., Ma, Y., Niu, G., & Chen, X. S. (2012) · Theranostics · doi:10.7150/thno.5276 · Cited by 67
“GLP-1 is a very unstable peptide, presumably by evolutionary design, such that the signal from binding of a radioligand to GLP-1 could be rapidly turned off by enzymatic degradation of the peptide [7].”
BackgroundMechanisms of surgical control of type 2 diabetes: GLP-1 is key factor
Holst, J. J., & Madsbad, S. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.033 · Cited by 67
“GLP-1 is metabolized immediately after its release by the enzyme, dipeptidylpeptidase-4 (DPP-4) [30], which cleaves off the N-terminal dipeptide leaving a metabolite (GLP-1 9–36 amide), which is devoid of insulinotropic activity.”
BackgroundSelf-citationSitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of Today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 66
Enhancing the Action of Incretin Hormones: A New Whey Forward?
Drucker, D. J. (2006) · Endocrinology · doi:10.1210/en.2006-0494 · Cited by 73
“The importance of intestinal DPP-4 for control of incretin degradation is illustrated by observations demonstrating that the majority of circulating incretin hormones represent the cleaved inactive moieties (11), implying very rapid degradation of both GLP-1 and GIP very soon after their release from enteroendocrine c…”
BackgroundWettergren, A., Pridal, L., Wøjdemann, M., & Holst, J. J. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00044-5 · Cited by 77
Self-citationHunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65
“Both forms are rapidly degraded by the serine protease dipeptidyl peptidase-4 (DPP-4), resulting in the generation of the truncated peptides GLP-1 (9–36 amide) and GLP-1 (9–37) [15].”
BackgroundSelf-citationIncretin‐based therapies – review of the physiology, pharmacology and emerging clinical experience
Martin, J. H., Deacon, C. F., Gorrell, M. D., & Prins, J. B. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02439.x · Cited by 76
Self-citationPeptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Schirra, J., Leicht, P., Hildebrand, P., Beglinger, C., Arnold, R., Goke, B., & Katschinski, M. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560177 · Cited by 65
“However, as it is known from studies with application of exogenous GLP-1(7–36)amide (Deacon et al. 1995b, Gutniak et al. 1996), bioactive GLP-1(7– 36)amide parallels the time course of total truncated GLP-1 immunoreactivity, but the elevation lasts for a shorter period.”
BackgroundMethodDipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience
Derosa, G., & Maffioli, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0204 · Cited by 64
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 63
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“GLP-1 is cleaved by the widely expressed ubiquitous enzyme aminopeptidase dipeptidyl peptidase IV (DPP-IV) in capillary endothelial cells [36-38].”
BackgroundHe, Y., Sabo, R., Campestrini, J., Wang, Y., Ligueros‐Saylan, M., Lasseter, K. C., Dilzer, S. C., Howard, D., & Dole, W. P. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0312-6 · Cited by 66
“Vildagliptin (LAF237) is a potent, selective, orally active DPP-4 inhibitor developed for the treatment of type 2 diabetes mellitus.”
Controlled release of biologics for the treatment of type 2 diabetes
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.002 · Cited by 68
“The short halflife of GLP-1 is largely attributed to rapid inactivation by the enzyme dipeptidyl-peptidase IV (DPP-IV)[97], a ubiquitous cell-surface serine protease that selectively cleaves off N-terminal dipeptides that have alanine or proline in the second position[98].”
InfluentialDPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy
Tang, P. M., Zhang, Y., Hung, J. S.-C., Chung, J. Y., Huang, X., To, K., & Lan, H.-Y. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.017 · Cited by 71
RetractedStrategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
“GLP-1 is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) and only has a half-life of 2 minutes [Deacon et al. 1995].”
BackgroundIdentification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7–36) analog
Léger, R., Thibaudeau, K., Robitaille, M., Quraishi, O., van Wyk, P., Bousquet-Gagnon, N., Carette, J., Castaigne, J., & Bridon, D. P. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.066 · Cited by 63
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
BackgroundIn vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans
Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., Rosenkilde, M. M., Madsbad, S., & Holst, J. J. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00394.2015 · Cited by 61
“Anorexigenic effects of PYY3–36 have been demonstrated in several studies with intravenous administration of PYY3–36 (6, 16, 32, 34), whereas infusions of PYY1–36 have no effect on food intake (34), suggesting that the cleavage of PYY1–36 to PYY3–36 is not as complete and rapid as for GLP-1 (34).”
BackgroundSelf-citationWhy is it so difficult to measure glucagon-like peptide-1 in a mouse?
Windeløv, J. A., Albrechtsen, N. J. W., Kuhre, R. E., Jepsen, S. L., Hornburg, D., Pedersen, J., Jensen, E. P., Galsgaard, K. D., Winther‐Sørensen, M., Ørgaard, A., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4347-7 · Cited by 69
“Previously validated sandwich total GLP-1 ELISAs [30] have been shown to be reliable for measuring total GLP-1 in humans, presumably because GLP-1(9–36)NH2 is degraded relatively slowly in humans [6], and this also seems to be the case in rats [38].”
BackgroundSelf-citationBiester, T., Muller, I., von dem Berge, T., Atlas, E., Nimri, R., Phillip, M., Battelino, T., Bratina, N., Dovc, K., Scheerer, M. F., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14258 · Cited by 61
“EZHGIP54K, Tecan Sunrise, Millipore Corporation, Billerica, MA, USA) and glucagon (RIA, Perkin Elmer Wizard 2, Eurodiagnostica, Medeon, Sweden), according to the manufacturer's instructions, were measured as an exploratory analysis in the samples from the first meal test in the young adult population only.(22,23)”
MethodA synthetic glucagon-like peptide-1 analog with improved plasma stability
Ritzel, U., Leonhardt, U., Ottleben, M., Ruhmann, A., Eckart, K., Spiess, J., & Ramadori, G. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590093 · Cited by 61
“Physio-logically, GLP-1 is degraded by plasma dipeptidyl-peptidase IV (DPP IV) with a half-life of 12–30 min (Deacon et al .”
BackgroundDalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Kuhre, R. E., Albrechtsen, N. J. W., Windeløv, J. A., Svendsen, B., Hartmann, B., & Holst, J. J. (2014) · Peptides · doi:10.1016/j.peptides.2014.01.020 · Cited by 61
“[3] Deacon CF, Johnsen AH, Holst JJ.”
BackgroundSelf-citationJean, M., Alameh, M., Buschmann, M. D., & Merzouki, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.25 · Cited by 69
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 63
“5), resulted in rapid N-terminal truncation and conversion of GIP1-42 and GLP-17-36 to the non-insulinotropic peptides GIP3-42 and GLP-19-36, respectively (52-54) (Figure 2).”
BackgroundAdditive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 61
“This could be due to higher concentrations of the antagonistic metabolite GLP-1(9-36)-amide after subcutaneous infusion compared with intravenous infusion.”
BackgroundMethodSelf-citationDipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Deacon, C. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.533 · Cited by 59
“Soon thereafter, the metabolite arising from DPP-4-mediated degradation of GLP-1 was identified in vivo [22,23] and the suggestion was made that inhibition of this process may have a therapeutic application in the treatment of Type 2 diabetes [10].”
BackgroundSelf-citationMeier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
“However, growing evidence suggested that some of these metabolites may contribute to pleiotropic effects of GLP-1, irrespective of the GLP-1R [19,20].”
BackgroundWu, H., Wei, J., Zhao, X., Liu, Y., Chen, Z., Wei, K., Lu, J., Chen, W., Jiang, M., Li, S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10351 · Cited by 63
“ubiquitous proteolytic enzyme (mainly dipeptidyl peptidase-4 [DPP-4] in the plasma).(20) Therefore, replenishing persistently exogenous GLP-1 to avoid the proteolysis of DPP-4 or developing its analogs are better strategies for prolonging the biological efficacy of GLP-1.”
BackgroundHou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., & Zhang, J. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.133 · Cited by 57
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Role of plasma kallikrein in diabetes and metabolism
Zhou, Q., Fickweiler, W., & Feener, E. P. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0179 · Cited by 58
Deacon, C. F., & Holst, J. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00359-5 · Cited by 55
Self-citationHassan, M., Eskilsson, A., Nilsson, C., Jonsson, C., Jacobsson, H., Refai, E., Larsson, S., & Efendić, S. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00121-8 · Cited by 63
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., & Tanaka, I. (2003) · Metabolism · doi:10.1053/meta.2003.50014 · Cited by 60
Lu, W. J., Yang, Q., Sun, W., Woods, S. C., D'Alessio, D., & Tso, P. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00146.2007 · Cited by 55
“5 to 2 min, and the biological effect is even shorter (5, 6, 26).”
BackgroundKong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
“Unfortunately, with a rapid degradation by dipeptidyl peptidase IV (DPPIV), natural GLP-1 peptide has a half-life of only 2–3 min in plasma, affecting clinical applications (Deacon et al., 1995).”
BackgroundGlucagon and Glucagon-Like Peptides 1 and 2
Holst, J. J. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_35 · Cited by 56
“The metabolite thus generated, GLP-1 9-36amide or GLP-1 (9-37), is inactive with respect to insulin secretion (but may have other actions, see below) and may even act as a competitive antagonist at the GLP-1 receptor (Deacon et al. 1995; Knudsen and Pridal 1996) although its formation does not seem to result in antago…”
BackgroundSelf-citationGlucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis
Linnemann, A. K., Neuman, J. C., Battiola, T. J., Wisinski, J. A., Kimple, M. E., & Davis, D. B. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1030 · Cited by 54
Investigating Endogenous Peptides and Peptidases Using Peptidomics
Tinoco, A. D., & Saghatelian, A. (2011) · Biochemistry · doi:10.1021/bi200417k · Cited by 58
Gut hormones as pharmaceuticals
Holst, J. J. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00185-3 · Cited by 65
Self-citationApplications of dipeptidyl peptidase IV inhibitors in diabetes mellitus
McIntosh, C. H. S., Demuth, H., Kim, S.-J., Pospisilik, J. A., & Pederson, R. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.013 · Cited by 58
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.